NCT04235101View on ClinicalTrials.gov

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions
Solid Tumor
Interventions
DRUG

SYD985 + Niraparib

SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule

Trial Locations (6)

1000

Institut Jules Bordet, Brussels

2650

University Hospital Antwerp, BE, Antwerp

6500 HB

Radboud University Medical Center/ NL, Nijmegen

SM2 5PT

The Royal Marsden NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust/ UK, Manchester

NE7 7DN

The Newcastle upon Tyne Hospitals NHS Foundation Trust/UK, Newcastle

Sponsors

Lead Sponsor

Byondis B.V.
All Listed Sponsors
lead

Byondis B.V.

INDUSTRY